|
1
|
Gong Y, Woda BA and Jiang Z: Oncofetal
protein IMP3, a new cancer biomarker. Adv Anat Pathol. 21:191–200.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vikesaa J, Hansen TV, Jønson L, Borup R,
Wewer UM, Christiansen J and Nielsen FC: RNA-binding IMPs promote
cell adhesion and invadopodia formation. EMBO J. 25:1456–1468.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Xu H, Bourne PA, Spaulding BO and Wang HL:
High-grade neuroendocrine carcinomas of the lung express K homology
domain containing protein overexpressed in cancer but carcinoid
tumors do not. Hum Pathol. 38:555–563. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Goodman S, Zhang L, Cheng L and Jiang Z:
Differential expression of IMP3 between male and female mature
teratomas - immunohistochemical evidence of malignant nature.
Histopathology. 65:483–489. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li D, Yan D, Tang H, Zhou C, Fan J, Li S,
Wang X, Xia J, Huang F, Qiu G, et al: IMP3 is a novel prognostic
marker that correlates with colon cancer progression and
pathogenesis. Ann Surg Oncol. 16:3499–3506. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lok T, Chen L, Lin F and Wang HL:
Immunohistochemical distinction between intrahepatic
cholangiocarcinoma and pancreatic ductal adenocarcinoma. Hum
Pathol. 45:394–400. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Damasceno EA, Carneiro FP, Magalhães AV,
Carneiro MV, Takano GH, Vianna LM, Seidler HB, Castro TM,
Muniz-Junqueira MI, Amorim RF, et al: IMP3 expression in gastric
cancer: Association with clinicopathological features and HER2
status. J Cancer Res Clin Oncol. 140:2163–2168. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jeng YM, Chang CC, Hu FC, Chou HY, Kao HL,
Wang TH and Hsu HC: RNA-binding protein insulin-like growth factor
II mRNA-binding protein 3 expression promotes tumor invasion and
predicts early recurrence and poor prognosis in hepatocellular
carcinoma. Hepatology. 48:1118–1127. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jiang Z, Lohse CM, Chu PG, Wu CL, Woda BA,
Rock KL and Kwon ED: Oncofetal protein IMP3: A novel molecular
marker that predicts metastasis of papillary and chromophobe renal
cell carcinomas. Cancer. 112:2676–2682. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yan J, Wei Q, Jian W, Qiu B, Wen J, Liu J,
Fu B, Zhou X and Zhao T: IMP3 predicts invasion and prognosis in
human lung adenocarcinoma. Lung. 194:137–146. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schaeffer DF, Owen DR, Lim HJ, Buczkowski
AK, Chung SW, Scudamore CH, Huntsman DG, Ng SS and Owen DA:
Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3)
overexpression in pancreatic ductal adenocarcinoma correlates with
poor survival. BMC Cancer. 10:592010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jiang Z, Chu PG, Woda BA, Rock KL, Liu Q,
Hsieh CC, Li C, Chen W, Duan HO, McDougal S, et al: Analysis of
RNA-binding protein IMP3 to predict metastasis and prognosis of
renal-cell carcinoma: A retrospective study. Lancet Oncol.
7:556–564. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tosun Yildirim H and Sentürk N: Analysis
of IMP3 expression in prostate adenocarcinomas. Turk Patoloji Derg.
28:128–133. 2012.PubMed/NCBI
|
|
14
|
Chromecki TF, Cha EK, Pummer K, Scherr DS,
Tewari AK, Sun M, Fajkovic H, Roehrborn CG, Ashfaq R, Karakiewicz
PI, et al: Prognostic value of insulin-like growth factor II mRNA
binding protein 3 in patients treated with radical prostatectomy.
BJU Int. 110:63–68. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ikenberg K, Fritzsche FR, Zuerrer-Haerdi
U, Hofmann I, Hermanns T, Seifert H, Müntener M, Provenzano M,
Sulser T, Behnke S, et al: Insulin-like growth factor II mRNA
binding protein 3 (IMP3) is overexpressed in prostate cancer and
correlates with higher Gleason scores. BMC Cancer. 10:3412010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Szarvas T, Tschirdewahn S, Niedworok C,
Kramer G, Sevcenco S, Reis H, Shariat SF, Rübben H and vom Dorp F:
Prognostic value of tissue and circulating levels of IMP3 in
prostate cancer. Int J Cancer. 135:1596–1604. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kulaçoğlu S and Erkılınç G: Imp3
expression in benign and malignant thyroid tumors and hyperplastic
nodules. Balkan Med J. 32:30–37. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Slosar M, Vohra P, Prasad M, Fischer A,
Quinlan R and Khan A: Insulin-like growth factor mRNA binding
protein 3 (IMP3) is differentially expressed in benign and
malignant follicular patterned thyroid tumors. Endocr Pathol.
20:149–157. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yorukoglu A, Yalcin N, Avci A,
Cakalagaoglu F, Yaylali G, Akin F, Haciyanli M and Ozden A:
Significance of IMP3, nucleophosmin, and Ki-67 expression in
papillary thyroid carcinoma. Int J Surg Pathol. 23:5–12. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jin L, Seys AR, Zhang S, Erickson-Johnson
MR, Roth CW, Evers BR, Oliveira AM and Lloyd RV: Diagnostic utility
of IMP3 expression in thyroid neoplasms: A quantitative RT-PCR
study. Diagn Mol Pathol. 19:63–69. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yamamoto H, Arakaki K, Morimatsu K, Zaitsu
Y, Fujita A, Kohashi K, Hirahashi M, Motoshita J, Oshiro Y and Oda
Y: Insulin-like growth factor II messenger RNA-binding protein 3
expression in gastrointestinal mesenchymal tumors. Hum Pathol.
45:481–487. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cornejo K, Shi M and Jiang Z: Oncofetal
protein IMP3: A useful diagnostic biomarker for leiomyosarcoma. Hum
Pathol. 43:1567–1572. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee DJ, Xylinas E, Rieken M, Khani F,
Klatte T, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, et al:
Insulin-like growth factor messenger RNA-binding protein 3
expression helps prognostication in patients with upper tract
urothelial carcinoma. Eur Urol. 66:379–385. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xylinas E, Cha EK, Khani F, Kluth LA,
Rieken M, Volkmer BG, Hautmann R, Küfer R, Chen YT, Zerbib M, et
al: Association of oncofetal protein expression with clinical
outcomes in patients with urothelial carcinoma of the bladder. J
Urol. 191:830–841. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Del Gobbo A, Vaira V, Rocco E Guerini,
Palleschi A, Bulfamante G, Ricca D, Fiori S, Bosari S and Ferrero
S: The oncofetal protein IMP3: A useful marker to predict poor
clinical outcome in neuroendocrine tumors of the lung. J Thorac
Oncol. 9:1656–1661. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chang S, Oh MH, Ji SY, Han J, Kim TJ, Eom
M, Kwon KY, Ha SY, Choi YD, Lee CH, et al: Practical utility of
insulin-like growth factor II mRNA-binding protein 3, glucose
transporter 1, and epithelial membrane antigen for distinguishing
malignant mesotheliomas from benign mesothelial proliferations.
Pathol Int. 64:607–612. 2014.PubMed/NCBI
|
|
27
|
Üçer Ö, Dağli AF, Kiliçarslan A and Artaş
G: Value of Glut-1 and Koc markers in the differential diagnosis of
reactive mesothelial hyperplasia, malignant mesothelioma and
pulmonary adenocarcinoma. Turk Patoloji Derg. 29:94–100.
2013.PubMed/NCBI
|
|
28
|
Kononen J, Bubendorf L, Kallioniemi A,
Bärlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G
and Kallioniemi OP: Tissue microarrays for high-throughput
molecular profiling of tumor specimens. Nat Med. 4:844–847. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Steurer S, Singer JM, Rink M, Chun F,
Dahlem R, Simon R, Burandt E, Stahl P, Terracciano L, Schlomm T, et
al: MALDI imaging-based identification of prognostically relevant
signals in bladder cancer using large-scale tissue microarrays.
Urol Oncol. 32:1225–1233. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
von Loga K, Kohlhaussen J, Burkhardt L,
Simon R, Steurer S, Burdak-Rothkamm S, Jacobsen F, Sauter G and
Krech T: FGFR1 amplification is often homogeneous and strongly
linked to the squamous cell carcinoma subtype in esophageal
carcinoma. PLoS One. 10:e01418672015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Grob TJ, Kannengiesser I, Tsourlakis MC,
Atanackovic D, Koenig AM, Vashist YK, Klose H, Marx AH, Koops S,
Simon R, et al: Heterogeneity of ERBB2 amplification in
adenocarcinoma, squamous cell carcinoma and large cell
undifferentiated carcinoma of the lung. Mod Pathol. 25:1566–1573.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gebauer F, Tachezy M, Effenberger K, von
Loga K, Zander H, Marx A, Kaifi JT, Sauter G, Izbicki JR and
Bockhorn M: Prognostic impact of CXCR4 and CXCR7 expression in
pancreatic adenocarcinoma. J Surg Oncol. 104:140–145. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mina S, Bohn BA, Simon R, Krohn A, Reeh M,
Arnold D, Bokemeyer C, Sauter G, Izbicki JR, Marx A, et al: PTEN
deletion is rare but often homogeneous in gastric cancer. J Clin
Pathol. 65:693–698. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Hammer NA, Hansen T, Byskov AG, Rajpert-De
Meyts E, Grøndahl ML, Bredkjaer HE, Wewer UM, Christiansen J and
Nielsen FC: Expression of IGF-II mRNA-binding proteins (IMPs) in
gonads and testicular cancer. Reproduction. 130:203–212. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tang H, Wei Q, Ge J, Jian W, Liu J, Zhong
L, Fu B and Zhao T: IMP3 as a supplemental diagnostic marker for
Hodgkin lymphoma. Hum Pathol. 44:2167–2172. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pryor JG, Simon RA, Bourne PA, Spaulding
BO, Scott GA and Xu H: Merkel cell carcinoma expresses K homology
domain-containing protein overexpressed in cancer similar to other
high-grade neuroendocrine carcinomas. Hum Pathol. 40:238–243. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Vranic S, Gurjeva O, Frkovic-Grazio S,
Palazzo J, Tawfik O and Gatalica Z: IMP3, a proposed novel basal
phenotype marker, is commonly overexpressed in adenoid cystic
carcinomas but not in apocrine carcinomas of the breast. Appl
Immunohistochem Mol Morphol. 19:413–416. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chokoeva AA, Ananiev J, Wollina U, Tana C,
Lotti T, Cardoso JC and Tchernev G: Imp-3 expression in benign
melanocytic nevi, dysplastic nevi and malignant melanoma:
preliminary findings in Bulgarian patients. J Biol Regul Homeost
Agents. 29:695–699. 2015.PubMed/NCBI
|
|
39
|
Shooshtarizadeh T, Nazeri A, Zare-Mirzaie
A and Movahedinia S: Expression of insulin-like growth factor II
mRNA binding protein 3 (IMP3) in enchondroma and chondrosarcoma.
Pathol Res Pract. 212:335–339. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lee AF, Gown AM and Churg A: IMP3 and
GLUT-1 immunohistochemistry for distinguishing benign from
malignant mesothelial proliferations. Am J Surg Pathol. 37:421–426.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ikeda K, Tate G, Suzuki T, Kitamura T and
Mitsuya T: IMP3/L523S, a novel immunocytochemical marker that
distinguishes benign and malignant cells: The expression profiles
of IMP3/L523S in effusion cytology. Hum Pathol. 41:745–750. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Pryor JG, Bourne PA, Yang Q, Spaulding BO,
Scott GA and Xu H: IMP-3 is a novel progression marker in malignant
melanoma. Mod Pathol. 21:431–437. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Yantiss RK, Woda BA, Fanger GR, Kalos M,
Whalen GF, Tada H, Andersen DK, Rock KL and Dresser K: KOC (K
homology domain containing protein overexpressed in cancer): A
novel molecular marker that distinguishes between benign and
malignant lesions of the pancreas. Am J Surg Pathol. 29:188–195.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nielsen J, Christiansen J, Lykke-Andersen
J, Johnsen AH, Wewer UM and Nielsen FC: A family of insulin-like
growth factor II mRNA-binding proteins represses translation in
late development. Mol Cell Biol. 19:1262–1270. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Mueller-Pillasch F, Pohl B, Wilda M,
Lacher U, Beil M, Wallrapp C, Hameister H, Knöchel W, Adler G and
Gress TM: Expression of the highly conserved RNA binding protein
KOC in embryogenesis. Mech Dev. 88:95–99. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lu D, Vohra P, Chu PG, Woda B, Rock KL and
Jiang Z: An oncofetal protein IMP3: A new molecular marker for the
detection of esophageal adenocarcinoma and high-grade dysplasia. Am
J Surg Pathol. 33:521–525. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Szarvas T, vom Dorp F, Niedworok C,
Melchior-Becker A, Fischer JW, Singer BB, Reis H, Bánkfalvi Á,
Schmid KW, Romics I, et al: High insulin-like growth factor
mRNA-binding protein 3 (IMP3) protein expression is associated with
poor survival in muscle-invasive bladder cancer. BJU Int.
110:E308–E317. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Findeis-Hosey JJ and Xu H: Insulin-like
growth factor II-messenger RNA-binding protein-3 and lung cancer.
Biotech Histochem. 87:24–29. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wang L, Li HG, Xia ZS, Lü J and Peng TS:
IMP3 is a novel biomarker to predict metastasis and prognosis of
gastric adenocarcinoma: A retrospective study. Chin Med J (Engl).
123:3554–3558. 2010.PubMed/NCBI
|
|
50
|
Morimatsu K, Aishima S, Yamamoto H,
Hayashi A, Nakata K and Oda Y, Shindo K, Fujino M, Tanaka M and Oda
Y: Insulin-like growth factor II messenger RNA-binding protein-3 is
a valuable diagnostic and prognostic marker of intraductal
papillary mucinous neoplasm. Hum Pathol. 44:1714–1721. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Chen L, Xie Y, Li X, Gu L, Gao Y, Tang L,
Chen J and Zhang X: Prognostic value of high IMP3 expression in
solid tumors: A meta-analysis. Onco Targets Ther. 10:2849–2863.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Schraml P, Bucher C, Bissig H, Nocito A,
Haas P, Wilber K, Seelig S, Kononen J, Mihatsch MJ, Dirnhofer S, et
al: Cyclin E overexpression and amplification in human tumours. J
Pathol. 200:375–382. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Lugli A, Forster Y, Haas P, Nocito A,
Bucher C, Bissig H, Mirlacher M, Storz M, Mihatsch MJ and Sauter G:
Calretinin expression in human normal and neoplastic tissues: A
tissue microarray analysis on 5233 tissue samples. Hum Pathol.
34:994–1000. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Went PT, Dirnhofer S, Bundi M, Mirlacher
M, Schraml P, Mangialaio S, Dimitrijevic S, Kononen J, Lugli A,
Simon R, et al: Prevalence of KIT expression in human tumors. J
Clin Oncol. 22:4514–4522. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Minner S, Luebke AM, Kluth M, Bokemeyer C,
Jänicke F, Izbicki J, Schlomm T, Sauter G and Wilczak W: High level
of Ets-related gene expression has high specificity for prostate
cancer: A tissue microarray study of 11 483 cancers.
Histopathology. 61:445–453. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Andersen CL, Monni O, Wagner U, Kononen J,
Bärlund M, Bucher C, Haas P, Nocito A, Bissig H, Sauter G, et al:
High-throughput copy number analysis of 17q23 in 3520 tissue
specimens by fluorescence in situ hybridization to tissue
microarrays. Am J Pathol. 161:73–79. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Almanzar G, Olkhanud PB, Bodogai M,
Dell'agnola C, Baatar D, Hewitt SM, Ghimenton C, Tummala MK,
Weeraratna AT, Hoek KS, et al: Sperm-derived SPANX-B is a
clinically relevant tumor antigen that is expressed in human tumors
and readily recognized by human CD4+ and CD8+ T cells. Clin Cancer
Res. 15:1954–1963. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Erez A, Perelman M, Hewitt SM, Cojacaru G,
Goldberg I, Shahar I, Yaron P, Muler I, Campaner S, Amariglio N, et
al: Sil overexpression in lung cancer characterizes tumors with
increased mitotic activity. Oncogene. 23:5371–5377. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Geiszt M, Lekstrom K, Brenner S, Hewitt
SM, Dana R, Malech HL and Leto TL: NAD(P)H oxidase 1, a product of
differentiated colon epithelial cells, can partially replace
glycoprotein 91phox in the regulated production of superoxide by
phagocytes. J Immunol. 171:299–306. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Dicken BJ, Graham K, Hamilton SM, Andrews
S, Lai R, Listgarten J, Jhangri GS, Saunders LD, Damaraju S and
Cass C: Lymphovascular invasion is associated with poor survival in
gastric cancer: An application of gene-expression and tissue array
techniques. Ann Surg. 243:64–73. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Mirlacher M, Kasper M, Storz M, Knecht Y,
Dürmüller U, Simon R, Mihatsch MJ and Sauter G: Influence of slide
aging on results of translational research studies using
immunohistochemistry. Mod Pathol. 17:1414–1420. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Mhawech-Fauceglia P, Herrmann FR, Rai H,
Tchabo N, Lele S, Izevbaye I, Odunsi K and Cheney RT: IMP3
distinguishes uterine serous carcinoma from endometrial
endometrioid adenocarcinoma. Am J Clin Pathol. 133:899–908. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Zheng W, Yi X, Fadare O, Liang SX, Martel
M, Schwartz PE and Jiang Z: The oncofetal protein IMP3: A novel
biomarker for endometrial serous carcinoma. Am J Surg Pathol.
32:304–315. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Yi X and Zheng W: Endometrial glandular
dysplasia and endometrial intraepithelial neoplasia. Curr Opin
Obstet Gynecol. 20:20–25. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Li C, Zota V, Woda BA, Rock KL, Fraire AE,
Jiang Z, Lu D, Xu B, Dresser K, Lutman CV, et al: Expression of a
novel oncofetal mRNA-binding protein IMP3 in endometrial
carcinomas: Diagnostic significance and clinicopathologic
correlations. Mod Pathol. 20:1263–1268. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Kazeminezhad B, Mirafsharieh SA, Dinyari
K, Azizi D and Ebrahimi A: Usefulness of insulin-like growth factor
II mRNA-binding protein 3 (IMP3) as a new marker for the diagnosis
of esophageal adenocarcinoma in challenging cases. Turk J
Gastroenterol. 25:253–256. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Feng W, Zhou Z, Peters JH, Khoury T, Zhai
Q, Wei Q, Truong CD, Song SW and Tan D: Expression of insulin-like
growth factor II mRNA-binding protein 3 in human esophageal
adenocarcinoma and its precursor lesions. Arch Pathol Lab Med.
135:1024–1031. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
He Y, Li L, Jiang W, Wang DQ, Xu L, Huang
Q, Zhang Y and Yang KX: Expression of the insulin-like growth
factor-II mRNA-binding protein 3 (IMP3) and carcinoembryonic
antigen (CEA) in mucinous minimal deviation adenocarcinoma. Pathol
Res Pract. 207:295–299. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Wachter DL, Schlabrakowski A, Hoegel J,
Kristiansen G, Hartmann A and Riener MO: Diagnostic value of
immunohistochemical IMP3 expression in core needle biopsies of
pancreatic ductal adenocarcinoma. Am J Surg Pathol. 35:873–877.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Lin L, Zhang J, Wang Y, Zheng L, Lin Z and
Cai Y: Expression of insulin-like growth factor 2 mRNA-binding
protein 3 expression and analysis of prognosis in the patients with
lung squamous cell carcinoma. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi.
29:694–697. 2013.(In Chinese). PubMed/NCBI
|
|
71
|
Perak R Beljan, Durdov MG, Capkun V,
Ivcevic V, Pavlovic A, Soljic V and Peric M: IMP3 can predict
aggressive behaviour of lung adenocarcinoma. Diagn Pathol.
7:1652012. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Findeis-Hosey JJ, Yang Q, Spaulding BO,
Wang HL and Xu H: IMP3 expression is correlated with histologic
grade of lung adenocarcinoma. Hum Pathol. 41:477–484. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Chen ST, Jeng YM, Chang CC, Chang HH,
Huang MC, Juan HF, Hsu CH, Lee H, Liao YF, Lee YL, et al:
Insulin-like growth factor II mRNA-binding protein 3 expression
predicts unfavorable prognosis in patients with neuroblastoma.
Cancer Sci. 102:2191–2198. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Takata A, Takiguchi S, Okada K, Takahashi
T, Kurokawa Y, Yamasaki M, Miyata H, Nakajima K, Mori M and Doki Y:
Expression of insulin-like growth factor-II mRNA-binding protein-3
as a marker for predicting clinical outcome in patients with
esophageal squamous cell carcinoma. Oncol Lett. 8:2027–2031.
2014.PubMed/NCBI
|
|
75
|
King RL, Pasha T, Roullet MR, Zhang PJ and
Bagg A: IMP-3 is differentially expressed in normal and neoplastic
lymphoid tissue. Hum Pathol. 40:1699–1705. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Gaete S: Consciousness as meaning. Actas
Luso Esp Neurol Psiquiatr. 28:306–330. 1969.(In Spanish).
PubMed/NCBI
|
|
77
|
Minato H, Kurose N, Fukushima M, Nojima T,
Usuda K, Sagawa M, Sakuma T, Ooi A, Matsumoto I, Oda M, et al:
Comparative immunohistochemical analysis of IMP3, GLUT1, EMA,
CD146, and desmin for distinguishing malignant mesothelioma from
reactive mesothelial cells. Am J Clin Pathol. 141:85–93. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Shi J, Liu H, Wang HL, Prichard JW and Lin
F: Diagnostic utility of von Hippel-Lindau gene product, maspin,
IMP3, and S100P in adenocarcinoma of the gallbladder. Hum Pathol.
44:503–511. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Yu L, Xu H, Wasco MJ, Bourne PA and Ma L:
IMP-3 expression in melanocytic lesions. J Cutan Pathol.
37:316–322. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Elshafey MR, Ahmed RA, Mourad MI and
Gaballah ET: The oncofetal protein IMP3 is an indicator of early
recurrence and poor outcome in mucoepidermoid carcinoma of salivary
glands. Cancer Biol Med. 13:286–295. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Ismerim AB, Ferreira SV, Lessa AM, Júnior
AS Pereira, Gurgel CA, Coutinho-Camillo CM, Soares FA, Vilas-Bôas
DS, Vidal MT and Santos JN: Insulin-like growth factor ii messenger
RNA-binding protein 3 in salivary gland tumors. Appl
Immunohistochem Mol Morphol. 24:422–426. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Chisté M, Alexis J and Recine M: IMP3
expression in serous tumors of the ovary. Appl Immunohistochem Mol
Morphol. 22:658–662. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Hu S, Wu X, Zhou B, Xu Z, Qin J, Lu H, Lv
L, Gao Y, Deng L, Yin J, et al: IMP3 combined with CD44s, a novel
predictor for prognosis of patients with hepatocellular carcinoma.
J Cancer Res Clin Oncol. 140:883–893. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Wachter DL, Kristiansen G, Soll C,
Hellerbrand C, Breuhahn K, Fritzsche F, Agaimy A, Hartmann A and
Riener MO: Insulin-like growth factor II mRNA-binding protein 3
(IMP3) expression in hepatocellular carcinoma. A
clinicopathological analysis with emphasis on diagnostic value.
Histopathology. 60:278–286. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Soddu S, Di Felice E, Cabras S,
Castellanos ME, Atzori L, Faa G and Pilloni L: IMP-3 expression in
keratoacanthomas and squamous cell carcinomas of the skin: An
immunohistochemical study. Eur J Histochem. 57:e62013. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Denby KS, Briones AJ, Bourne PA, Spaulding
BO, Lu D, Fischer-Colbrie R, Qu Z, Wang HL and Xu H: IMP3, NESP55,
TTF-1 and CDX2 serve as an immunohistochemical panel in the
distinction among small-cell carcinoma, gastrointestinal carcinoid,
and pancreatic endocrine tumor metastasized to the liver. Appl
Immunohistochem Mol Morphol. 20:573–579. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Li C, Rock KL, Woda BA, Jiang Z, Fraire AE
and Dresser K: IMP3 is a novel biomarker for adenocarcinoma in situ
of the uterine cervix: An immunohistochemical study in comparison
with p16(INK4a) expression. Mod Pathol. 20:242–247. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Kumara H Shantha, Kirchoff D, Caballero
OL, Su T, Ahmed A, Herath SA, Njoh L, Cekic V, Simpson AJ,
Cordon-Cardo C, et al: Expression of the cancer testis antigen
IGF2BP3 in colorectal cancers; IGF2BP3 holds promise as a specific
immunotherapy target. Oncoscience. 2:607–614. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Lochhead P, Imamura Y, Morikawa T, Kuchiba
A, Yamauchi M, Liao X, Qian ZR, Nishihara R, Wu K, Meyerhardt JA,
et al: Insulin-like growth factor 2 messenger RNA binding protein 3
(IGF2BP3) is a marker of unfavourable prognosis in colorectal
cancer. Eur J Cancer. 48:3405–3413. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Liu W, Wang P, Li Z, Xu W, Dai L, Wang K
and Zhang J: Evaluation of tumour-associated antigen (TAA)
miniarray in immunodiagnosis of colon cancer. Scand J Immunol.
69:57–63. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Barton VN, Donson AM, Birks DK,
Kleinschmidt-DeMasters BK, Handler MH, Foreman NK and Rush SZ:
Insulin-like growth factor 2 mRNA binding protein 3 expression is
an independent prognostic factor in pediatric pilocytic and
pilomyxoid astrocytoma. J Neuropathol Exp Neurol. 72:442–449. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Bellezza G, Prosperi E, Del Sordo R,
Colella R, Rulli A and Sidoni A: IMP3 is strongly expressed in
malignant phyllodes tumors of the breast: An immunohistochemical
study. Int J Surg Pathol. 24:37–42. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Walter O, Prasad M, Lu S, Quinlan RM,
Edmiston KL and Khan A: IMP3 is a novel biomarker for triple
negative invasive mammary carcinoma associated with a more
aggressive phenotype. Hum Pathol. 40:1528–1533. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Hoffmann NE, Sheinin Y, Lohse CM, Parker
AS, Leibovich BC, Jiang Z and Kwon ED: External validation of IMP3
expression as an independent prognostic marker for metastatic
progression and death for patients with clear cell renal cell
carcinoma. Cancer. 112:1471–1479. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Sitnikova L, Mendese G, Liu Q, Woda BA, Lu
D, Dresser K, Mohanty S, Rock KL and Jiang Z: IMP3 predicts
aggressive superficial urothelial carcinoma of the bladder. Clin
Cancer Res. 14:1701–1706. 2008. View Article : Google Scholar : PubMed/NCBI
|
